EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma

Muhammad Ali, Mathias Bressel, David Chang, Sheng F Oon, Rajeev Ravi, Daniel Moon, Declan G Murphy iD, Renu S Eapen, Marlon Perera, Nathan Lawrentschuk iD, Arun A Azad iD, Sarat Chander iD und 3 weitere

BJU International · 2025

DOI: 10.1111/bju.16843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Muhammad Ali und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Radiosurgery, Kidney Neoplasms, Carcinoma, Renal Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the predictive value of the R.E.N.A.L. ([R]adius, [E]xophytic/endophytic properties, [N]earness of tumour to the collecting system or sinus, [A]nterior/posterior descriptor, and [L]ocation relative to polar lines) nephrometry score (RNS) for outcomes following stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma (RCC), as the impact of tumour complexity on outcomes following nephron‐sparing SABR treatment is unclear. Patients and Methods This was a single institutional retrospective analysis of patients with primary RCC receiving SABR between 2012 and 2020. The primary outcome was the change in renal function post‐SABR, measured by estimated glomerular filtration rate (eGFR), and the effect of baseline RNS on it was assessed using linear mixed models (LMMs).

Results

A total of 90 patients with a median (interquartile range [IQR]) age of 77 (71–82) years and a median (IQR) follow‐up of 4.8 (2.8–7.8) years were included. In all, 52 patients (58%) had T1b disease, nine (10%) had T2 disease, and three (3%) had T3 disease. The median (IQR) maximum tumour size was 4.6 (2.1–8.4) cm. Most patients had moderate–complex renal tumours with a median (IQR) RNS of 9 (7–10). The baseline median eGFR was 53.6 mL/min/1.73 m 2 (95% confidence interval [CI] 49.7–57.5 mL/min/1.73 m 2 ). The eGFR declined by −8.1 mL/min/1.73 m 2 (95% CI −6.5 to −9.6 mL/min/1.73 m 2 ) at 1 year. The P value for the post‐SABR eGFR trajectory according to baseline RNS was P = 0.06. Two patients (2.2%) underwent dialysis. Three patients (3.3%) experienced local progression. The 3‐ and 5‐year estimates for freedom from local failure were 97% (95% CI 89–99%), and 91% (95% CI 68–98%), respectively. Four (4.4%) patients experienced Grade 3 toxicities.

Conclusion

Stereotactic ablative body radiotherapy is an effective treatment option, with acceptable decline in renal function and toxicity for medically inoperable patients with complex primary kidney tumours. The association between baseline RNS and renal function trajectories is worthy of further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryKidney NeoplasmsCarcinoma, Renal CellHumansRetrospective StudiesMaleAgedFemaleAged, 80 and overGlomerular Filtration RateTreatment Outcome

Stichwörter der Autor:innen

PADUAR.E.N.A.L. nephrometry score (RNS)RCCSABRSBRTkidney cancernephron sparingradiation ablationrenal function

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Royal Melbourne Clinical School, University of Melbourne, Melbourne, Australia.

ORCID-Profile: Declan G Murphy, Nathan Lawrentschuk, Arun A Azad, Sarat Chander

Zitieren

APA

Ali, M., Bressel, M., Chang, D., Oon, S. F., Ravi, R., Moon, D., Murphy, D. G., Eapen, R. S., Perera, M., Lawrentschuk, N., Azad, A. A., Chander, S., Shaw, M., Hardcastle, N., & Siva, S. (2025). Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma. BJU International. https://doi.org/10.1111/bju.16843

Vancouver

Ali M, Bressel M, Chang D, Oon SF, Ravi R, Moon D, et al. Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma. BJU International. 2025. doi:10.1111/bju.16843

BibTeX
@article{Ali2025,
  author = {Ali, Muhammad and Bressel, Mathias and Chang, David and Oon, Sheng F and Ravi, Rajeev and Moon, Daniel and Murphy, Declan G and Eapen, Renu S and Perera, Marlon and Lawrentschuk, Nathan and Azad, Arun A and Chander, Sarat and Shaw, Mark and Hardcastle, Nicholas and Siva, Shankar},
  title = {Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16843}
}
Kostenlos starten →